Literature DB >> 27418469

A Simple Automated Method for Detecting Recurrence in High-Grade Glioma.

T K Yanagihara1, J Grinband2, J Rowley3, K A Cauley2,4, A Lee3, M Garrett3, M Afghan3,5, A Chu3, T J C Wang3,6.   

Abstract

Our aim was to develop an automated multiparametric MR imaging analysis of routinely acquired imaging sequences to identify areas of focally recurrent high-grade glioma. Data from 141 patients treated with radiation therapy with a diagnosis of high-grade glioma were reviewed. Strict inclusion/exclusion criteria identified a homogeneous cohort of 12 patients with a nodular recurrence of high-grade glioma that was amenable to focal re-irradiation (cohort 1). T1WI, FLAIR, and DWI data were used to create subtraction maps across time points. Linear regression was performed to identify the pattern of change in these 3 imaging sequences that best correlated with recurrence. The ability of these parameters to guide treatment decisions in individual patients was assessed in a separate cohort of 4 patients who were treated with radiosurgery for recurrent high-grade glioma (cohort 2). A leave-one-out analysis of cohort 1 revealed that automated subtraction maps consistently predicted the radiologist-identified area of recurrence (median area under the receiver operating characteristic curve = 0.91). The regression model was tested in preradiosurgery MRI in cohort 2 and identified 8 recurrent lesions. Six lesions were treated with radiosurgery and were controlled on follow-up imaging, but the remaining 2 lesions were not treated and progressed, consistent with the predictions of the model. Multiparametric subtraction maps can predict areas of nodular progression in patients with previously treated high-grade gliomas. This automated method based on routine imaging sequences is a valuable tool to be prospectively validated in subsequent studies of treatment planning and posttreatment surveillance.
© 2016 by American Journal of Neuroradiology.

Entities:  

Year:  2016        PMID: 27418469      PMCID: PMC5237423          DOI: 10.3174/ajnr.A4873

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 2.  Imaging of the Posttherapeutic Brain.

Authors:  Bruno A Telles; Francesco D'Amore; Alexander Lerner; Meng Law; Mark S Shiroishi
Journal:  Top Magn Reson Imaging       Date:  2015-06

3.  The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections.

Authors:  R O Barnard; J F Geddes
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

4.  Prediction of glioma recurrence using dynamic ¹⁸F-fluoroethyltyrosine PET.

Authors:  T Pyka; J Gempt; F Ringel; S Hüttinger; S van Marwick; S Nekolla; H-J Wester; M Schwaiger; S Förster
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-12       Impact factor: 3.825

5.  Dynamic T1-weighted spin-echo MR imaging: the role of digital subtraction in the demonstration of enhancing brain lesions.

Authors:  E R Melhem; N R Mehta
Journal:  J Magn Reson Imaging       Date:  1999-04       Impact factor: 4.813

6.  Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.

Authors:  A J Prager; N Martinez; K Beal; A Omuro; Z Zhang; R J Young
Journal:  AJNR Am J Neuroradiol       Date:  2015-01-15       Impact factor: 3.825

7.  Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression.

Authors:  Jihoon Cha; Sung Tae Kim; Hyung-Jin Kim; Hye Jeong Kim; Byung-Joon Kim; Pyoung Jeon; Keon Ha Kim; Hong Sik Byun
Journal:  Eur Radiol       Date:  2012-08-19       Impact factor: 5.315

8.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 9.  Pseudoprogression and pseudoresponse in the treatment of gliomas.

Authors:  Dieta Brandsma; Martin J van den Bent
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

10.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Authors:  Benjamin M Ellingson; Hyun J Kim; Davis C Woodworth; Whitney B Pope; Jonathan N Cloughesy; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Timothy F Cloughesy
Journal:  Radiology       Date:  2013-11-27       Impact factor: 11.105

View more
  3 in total

1.  Radiomics-based convolutional neural network for brain tumor segmentation on multiparametric magnetic resonance imaging.

Authors:  Prateek Prasanna; Ayush Karnawat; Marwa Ismail; Anant Madabhushi; Pallavi Tiwari
Journal:  J Med Imaging (Bellingham)       Date:  2019-05-07

2.  Predictive Models in Differentiating Vertebral Lesions Using Multiparametric MRI.

Authors:  R Rathore; A Parihar; D K Dwivedi; A K Dwivedi; N Kohli; R K Garg; A Chandra
Journal:  AJNR Am J Neuroradiol       Date:  2017-10-12       Impact factor: 3.825

Review 3.  Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging.

Authors:  Vikram S Soni; Ted K Yanagihara
Journal:  Cancer Imaging       Date:  2019-11-29       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.